Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
B 194.25 2.27% 4.32
RGEN closed up 2.27 percent on Monday, March 18, 2024, on 53 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 50 DMA Bearish 2.27%
MACD Bearish Centerline Cross Bearish 2.27%
Bollinger Band Squeeze Range Contraction 2.27%
Multiple of Ten Bearish Other 2.27%
Bollinger Band Squeeze Range Contraction 0.35%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 13 hours ago
Rose Above Previous Day's High about 13 hours ago
20 DMA Resistance about 13 hours ago
Possible Inside Day about 14 hours ago
Rose Above 10 DMA about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Repligen Corporation Description

Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Chromatography Imaging Agent Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products

Is RGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 211.13
52 Week Low 110.46
Average Volume 572,243
200-Day Moving Average 167.40
50-Day Moving Average 191.28
20-Day Moving Average 194.43
10-Day Moving Average 193.92
Average True Range 5.66
RSI (14) 50.50
ADX 12.86
+DI 20.62
-DI 24.03
Chandelier Exit (Long, 3 ATRs) 194.16
Chandelier Exit (Short, 3 ATRs) 204.77
Upper Bollinger Bands 198.85
Lower Bollinger Band 190.01
Percent B (%b) 0.48
BandWidth 4.55
MACD Line -0.05
MACD Signal Line 0.68
MACD Histogram -0.7322
Fundamentals Value
Market Cap 10.85 Billion
Num Shares 55.8 Million
EPS 2.03
Price-to-Earnings (P/E) Ratio 95.69
Price-to-Sales 17.09
Price-to-Book 5.76
PEG Ratio 2.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 199.95
Resistance 3 (R3) 199.40 196.95 199.00
Resistance 2 (R2) 196.95 195.50 197.23 198.68
Resistance 1 (R1) 195.60 194.60 196.28 196.15 198.37
Pivot Point 193.15 193.15 193.49 193.43 193.15
Support 1 (S1) 191.80 191.70 192.48 192.35 190.13
Support 2 (S2) 189.35 190.80 189.63 189.82
Support 3 (S3) 188.00 189.35 189.50
Support 4 (S4) 188.55